PT - JOURNAL ARTICLE AU - Eleonora Porcu AU - Federica Gilardi AU - Liza Darrous AU - Loic Yengo AU - Nasim Bararpour AU - Marie Gasser AU - Pedro Marques Vidal AU - Philippe Froguel AU - Gerard Waeber AU - Aurelien Thomas AU - Zoltán Kutalik TI - Identification of metabolomics biomarkers for type 2 diabetes: triangulating evidence from longitudinal and Mendelian randomization analyses AID - 10.1101/2020.10.30.20222836 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.30.20222836 4099 - http://medrxiv.org/content/early/2020/11/03/2020.10.30.20222836.short 4100 - http://medrxiv.org/content/early/2020/11/03/2020.10.30.20222836.full AB - The number of people affected by Type 2 Diabetes Mellitus (T2DM) is close to half a billion and is on a sharp rise, representing a major and growing public health burden. As the case for many other complex diseases, early diagnosis is key to prevent irreversible end-organ damages. However, given its mild initial symptoms, T2DM is often diagnosed several years after its onset, leaving half of diabetic individuals undiagnosed. While several classical clinical and genetic biomarkers have been identified, improving early diagnosis by exploring other kinds of omics data remains crucial. In this study, we have combined longitudinal data from two population-based cohorts CoLaus and DESIR (comprising in total 493 incident cases vs 1’360 controls) to identify new or confirm previously implicated metabolomic biomarkers predicting T2DM incidence more than five years ahead of clinical diagnosis. Our longitudinal data have shown robust evidence for valine, leucine, carnitine and glutamic acid being predictive of future conversion to T2DM, and also confirmed to be causal by 2-sample Mendelian randomisation (based on independent data). Interestingly, for valine and leucine a strong reverse causal effect was detected, indicating that the genetic predisposition to T2DM may trigger early changes of these metabolites, which appear well-before any clinical symptoms. These findings indicate that molecular traits linked to the genetic basis of T2DM may be particularly promising early biomarkers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the Swiss National Science Foundation (#32473B-166450; FN 32003B_173092, and #31003A_182420).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CoLaus cohort: The study protocols were approved by the Ethical Committee of the Canton de Vaud and all participants provided written informed consent. DESIR cohort: All participants provided written informed consent and the study protocol was approved by the Ethics Committee for the Protection of Subjects for Biomedical Research of Bicentre Hospital, France.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe individual data from CoLAus and DESIR cohorts are not publicly available.